Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sigma-Aldrich Reports Net Income Of $84.4 Million For Q1 2009
Excluding a 10% currency impact, first quarter sales grew organically by 1% from a year ago. Organic sales for the Company’s Research business grew over 3%, with individual
Excluding a 10% currency impact, first quarter sales grew organically by 1% from a year ago. Organic sales for the Company’s Research business grew over 3%, with individual
NanoBio, a biopharmaceutical company, has reported that the FDA has approved the company’s investigational new drug application for the Phase I clinical study of NB-1008, a seasonal influenza
Pharmasset, a clinical-stage pharmaceutical company, has reported that after a discussion with its independent data safety monitoring board and the FDA, the company has decided to voluntarily terminate
Non-GAAP net income grew 10% to $288.1 million, or $1.04 per diluted share, compared with $260.9 million, or $0.95 per diluted share, in the same period last year.
GlaxoSmithKline, or GSK, and Stiefel Laboratories have signed an agreement to create a new specialist dermatology business. Under the terms of the agreement GSK will acquire the total
Medarex, a biopharmaceutical company, has reported encouraging preliminary data from an ongoing Phase I clinical trial of MDX-1401 in patients with relapsed or refractory Hodgkin’s lymphoma that demonstrated
Merck Serono, a division of German drug maker Merck KGaA, has launched Kuvan, an oral therapeutic indicated for the treatment of hyperphenylalaninaemia due to phenylketonuria or tetrahydrobiopterin deficiency,
Impax Pharmaceuticals, the brand products division of Impax Laboratories, has started a Phase III trial of IPX066 in Parkinson’s disease or PD patients based on encouraging interim data
US-based PerkinElmer has launched a new series of AlphaLISA No Wash immunoassay kits to help enable advanced biomarker research in multiple key disease states, including angiogenesis, inflammation and
French pharmaceutical group Sanofi-Aventis has announced an increase of capital investment in the amount of $90m to extend its current manufacturing facility located at the Beijing Economic and